Selecting Therapy for Advanced NSCLC Based on PDL1 and NGS T

Shared insight on the value that molecular testing and PDL1 testing, respectively, have on determining optimal therapy for patients with advanced non–small cell lung cancer.

Related Keywords

, Recent Updates , Translating Evidence , Clinical Practice , Lung Cancer , Non Small Cell Lung Cancer , Nsclc , Trio Therapy , Immunotherapy , Immune Checkpoint Inhibitors , Metastatic Nsclc , Metastatic Lung Cancer , Rings , Next Generation Sequencing , Ktmb , Tumor Mutational Burden , Molecular Testing , Genetic Testing , Ipi Nivo , Nivo Ipi , Ipilimumab , Nivolumab , Pdl1 Levels , Pdl1 Expression ,